Recombinant thrombomodulin ameliorates experimental autoimmune encephalomyelitis by suppressing high mobility group box 1 and inflammatory cytokines. (26th March 2018)

• Record Type: Journal Article
• Authors: Uzawa, A; Mori, M; Masuda, H; Ohtani, R; Uchida, T; Kuwabara, S
• Is Part Of: Clinical and experimental immunology. Volume 193:Number 1(2018:Jul.)
• Page Start: 47
• Page End: 54
• Publication Date: 2018-03-26
• Subjects: cytokine -- experimental autoimmune encephalomyelitis -- high mobility group box 1 -- multiple sclerosis -- thrombomodulin; Immunopathology -- Periodicals; 616.079
• DOI: 10.1111/cei.13123
• Languages: English
• ISSNs: 0009-9104

Abstract

Summary: Recombinant thrombomodulin (rTM) has pleiotrophic properties, including anti-coagulation and anti-inflammation; however, its effectiveness as a treatment for multiple sclerosis (MS) has not been evaluated fully. High mobility group box 1 (HMGB1) and proinflammatory cytokines, working as inflammatory mediators, are reportedly involved in the inflammatory pathogenesis of MS. The aim of this study was to determine whether rTM can be a potential therapeutic agent for experimental autoimmune encephalomyelitis (EAE). EAE mice received rTM treatment (1 mg or 0·1 mg/kg/day) from days 11 to 15 after immunization. The clinical variables, plasma levels of inflammatory cytokines and HMGB1 and pathological findings in EAE were evaluated. rTM administration ameliorated the clinical and pathological severity of EAE. An immunohistochemical study of the spinal cord showed weaker cytoplasmic HMGB1 staining in the rTM-treated EAE mice than in the untreated EAE mice. Plasma levels of inflammatory cytokines and HMGB1 were suppressed by rTM treatment. In conclusion, rTM down-regulated inflammatory mediators in the peripheral circulation and prevented HMGB1 release from nuclei in the central nervous system, suppressing EAE-related inflammation. rTM could have a novel therapeutic potential for patients with MS. Graphical Abstract: